Adwia Pharmaceuticals

ADWIA Pharmaceuticals manufactures generic medicines for human and animal health. Its human health portfolio covers anti-infectives, orthopedic treatments, gastroenterology, urology, men's health, antifungals, gynecology, oral hygiene, anti-asthmatic treatments, cardiometabolic medicines, non-narcotic analgesics, cough and cold products, and central nervous system therapies. The cardiovascular range includes treatments for hypertension, platelet-related conditions, heart failure, lipid control, and coronary conditions. It also produces treatments for neuropathic pain, osteoporosis, benign prostatic hyperplasia, urinary incontinence, erectile dysfunction, premature ejaculation, nausea, muscle spasms, reflux disease, and H. pylori infections. Its animal health division supplies analgesics, antipyretics, antibiotics, anti-inflammatories, anthelmintics, anti-blood parasite products, digestive stimulants, minerals, electrolytes, fertility products, sedatives, anesthetics, sulphonamides, and vitamins.

Established in 1984, the company expanded into production formulation and drug delivery in 1998. It operates pharmaceutical manufacturing under an Egyptian Drug Authority license at its facility in 10th of Ramadan City, supporting domestic and export markets, including Gulf Cooperation Council countries, Commonwealth of Independent States regions, and African nations. Its pharmaceutical quality system is aligned with GMP and Quality Risk Management and addresses product safety and efficacy, documentation, environmental health, and safety. The business reports adherence to GMP, GLP, GSP, Egyptian Drug Authority, World Health Organization, and ISO requirements. Its certifications include ISO 9001:2015 for quality management, ISO 14001:2015 for environmental management, ISO 45001:2018 for occupational health and safety management, and ISO 50001:2018 for energy management.